Insulin glargine appears to be equivalent to, if not more effective than, neutral protamine Hagedorn (NPH) insulin in improving HbA1c and fasting blood glucose (FBG) levels among patients with type I diabetes. Insulin glargine is a long-acting recombinant human insulin analog indicated for type I and type 2 diabetics.
A once-daily injection is thought to minimize hypoglycemia because of its prolonged absorption profile. Findings of two randomized trials were presented today (September 2) during the European Association for the Study of Diabetes (EASD) meeting, in Budapest, Hungary.
In one study, Dr. Greg Fulcher with the Royal North Shore Hospital, St Leonard’s, New South Wales, Australia, and colleagues randomized 49 male and 76 female patients with poorly controlled type I diabetes (HbA1c greater than 8.0 percent) to receive either insulin glargine or NPH insulin at bedtime for 30 weeks.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!